Navigation Links
/C O R R E C T I O N -- Mobidiag Ltd/
Date:4/21/2008

Mobidiag Releases First Microarray Based Rapid Test for Bacterial Detection

The Finnish biotechnology company Mobidiag announced today the Prove-it(TM) Bacteria test that sets a world record by being able to detect 50 dangerous bacteria simultaneously - including the widespread "superbug" MRSA. This is an important milestone in the battle against infectious diseases, most importantly life-threatening sepsis.

HELSINKI, April 21 /PRNewswire/ -- Sepsis is a growing cause of death worldwide - there are around 3 million sepsis cases annually, over 500,000 of them resulting in death. Sepsis is an infection caused by a number of micro-organisms spreading in the bloodstream. The challenge in sepsis treatment is starting adequate treatment with the appropriate antibiotics on time.

Currently, the diagnostics of causative pathogen(s) needed for the antibiotic treatment decision takes 2-5 days based on blood culturing and subsequent pathogen identification. Using Mobidiag's Prove-it(TM) Bacteria, the pathogen detection is available 1-3 days earlier compared to current diagnostics. The PCR and microarray-based test takes less than three hours to complete. Achieved time saving rationalizes antibiotic treatment and improves patient outcomes and decreases mortality considerably.

"Our Prove-it(TM) Bacteria test has all the potential to revolutionize microbial sepsis diagnostics. The test helps clinicians make better and faster decisions and provide sufficient treatment for seriously ill patients. This offers huge savings, as sepsis treatment currently consumes billions of euros annually. Our target is to have a single test that reliably detects the majority of dangerous human disease causing bacteria and Prove-it(TM) Bacteria test is an important milestone on that road," says Jaakko Pellosniemi, CEO of Mobidiag. "I strongly believe that Prove-it(TM) products will rapidly gain foothold on the multibillion microbial diagnostic markets."

Prove-it(TM) Bacteria test is initially intended for research purposes. The evaluation aiming for the European CE-IVD status enabling its use in clinical sepsis diagnostics is currently ongoing and will be completed later this year. The test will cover more than 90 % of all sepsis cases.

Founded in 2001, Mobidiag develops rapid diagnostic tests for hospital laboratories. The Prove-it(TM) Bacteria test is developed in co-operation with HUSLAB and Hospital Districts of Helsinki and Uusimaa, Finland.

Mobidiag Ltd is a Finnish biotechnology company developing, producing and marketing rapid diagnostic tests to hospital laboratories. The company focuses on clinical microbial diagnostics. More information on http://www.mobidiag.com
Press photos from here http://www.mobidiag.com/media/images

Additional information:

CEO Jaakko Pellosniemi, Mobidiag Ltd, tel. +358-40-501-1004

Press contact:

Ville Lehtovirta, Text 100 Conexio, tel. +358-50-346-6946

ville.lehtovirta@conexio.fi


'/>"/>
SOURCE Mobidiag Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... PHOENIX and SAN DIEGO ... (OTCQB:CELZ) announced the appointment of Santosh Kesari , ... Board. Dr. Kesari will leverage his experience in neurology and ... its adult stem cell for treatment of stroke. The AmnioStem ... amniotic fluid, which has previously shown therapeutic activity in ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) inhibited the direct neurotoxic effect of prion-like forms of Amyloid ...
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... report "Biomarkers - Technologies, Markets and Companies" to their ... , , ... biomarkers and their discovery using various -omics technologies such as proteomics ... biomarkers and new tests are also based on biomarker. ...
(Date:12/5/2016)... SAN DIEGO , Dec. 5, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and other chronic ... is joining the company as Chief Financial Officer ... Renova Therapeutics with 20 years of experience in ... closely held biotech and software companies. Most recently, ...
Breaking Biology Technology:
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
Breaking Biology News(10 mins):